Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
The safety and tolerance data of the preliminary results of a randomised, parallel group, multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in patients with myocardial infarction are presented. The frequency of side effects was similar in the 2 groups. The most frequently encountered side effect was bleeding, overwhelmingly from the groin puncture site from angiography. There was no significant difference between amount or incidence of bleeding complications between the two groups, as measured by number of bleeding episodes, transfusion requirements, or mean drop in haematocrit or haemoglobin.
Rothbard
R L
RL
University of Rochester, School of Medicine and Dentistry.
D016255:Anistreplase; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006400:Hematocrit; D006454:Hemoglobins / Q000187:drug effects; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010958:Plasminogen / Q000009:adverse effects* / Q000627:therapeutic use; D011897:Random Allocation; D013300:Streptokinase / Q000009:adverse effects* / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D006454:Hemoglobins; D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase